Occupational Activity – Page 9

Senate Hearing for RFK Jr. Amid Strong Public Support for Vaccine Access

3 months ago talkbio0Tagged Department of Health and, FDA-approved, Hearing, Homo sapiens, public entity, RFK Jr., Senate, Services, United States Food and Drug Administration, Vaccines

RFK Jr., Senate hearing, vaccine access, public support, FDA-approved vaccines, Department of Health and Human Services nomination

FDA Names Dr. Sara Brenner as Acting Commissioner

3 months ago talkbio0Tagged Dr. Sara Brenner, Food Safety, United States Food and Drug Administration

FDA, Acting Commissioner, Dr. Sara Brenner, Medical Devices, Food Safety

Sarepta Therapeutics Reports Encouraging Two-Year Data for ELEVIDYS in Duchenne Muscular Dystrophy, Projecting $1 Billion in Sales

3 months ago talkbio0Tagged Clinical Trials, DMD, Duchenne, ELEVIDYS, gene therapy, Muscular Dystrophy, Muscular Dystrophy, Duchenne, Projections, Sales - occupational activity

Sarepta Therapeutics, ELEVIDYS, Duchenne Muscular Dystrophy (DMD), Gene Therapy, Clinical Trial Results, Sales Projections

Biogen’s Strategic Pivot: Emphasizing External Collaborations and Diversification

3 months ago talkbio0Tagged Alzheimer 's disease, Biogen, diversification, Immunology, Nerve Degeneration, Neuroscience discipline, Research Strategy

Biogen, research strategy, external collaborations, diversification, Alzheimer’s disease, rare diseases, immunology, neuroscience, neurodegeneration

Tris Pharma’s Cebranopadol Shows Promising Results in Phase 3 Trial for Moderate-to-Severe Acute Pain Treatment

3 months ago talkbio0Tagged Acute onset pain, Administration occupational activities, Agonist, ALLEVIATE-1, Cebranopadol, Clinical Trials, Dual-NMR, Opioid Crisis, Pain, Phase 3, Tris Pharma

Cebranopadol, Tris Pharma, ALLEVIATE-1, Phase 3 Clinical Trial, Acute Pain Treatment, Dual-NMR Agonist, Opioid Crisis, Pain Management

Trump Revokes Biden’s Executive Order on AI Safety and Trustworthiness

3 months ago talkbio0Tagged Administration occupational activities, AI safety, Aortic Valve Insufficiency, Artificial (qualifier value), Biden Executive Order, governance, Regulation, Transplant Registry Unified Management Program

AI Safety, Biden Executive Order, Trump Administration, Artificial Intelligence Governance, AI Regulation

Sionna and Odyssey Therapeutics Kick Off 2025 Biotech IPO Wave with SEC Filings

3 months ago talkbio0Tagged 2025, File (record), Health care facility, Industry, IPO, JPM, Market, Odyssey, Sionna

Sionna Therapeutics, Odyssey Therapeutics, IPO filings, biotech industry, JPM Healthcare Conference, 2025 IPO market

Understanding the Second Round of Medicare Drug Price Negotiations: What Trump’s CMS Can and Can’t Change

3 months ago talkbio0Tagged Administration occupational activities, CMS, drug price, Inflation, Medicare, Myasthenic Syndromes, Congenital, negotiation, Prices, Transplant Registry Unified Management Program

Medicare drug price negotiation, Trump administration, CMS, Inflation Reduction Act, drug prices, negotiation process

Charles River Laboratories Forecasts Revenue Decline in 2025 Amid CDMO Challenges

3 months ago talkbio0Tagged 2025, Biopharma, business career, CDMO, Charles, constraints, Drug Industry, IL31RA gene, revenue outlook, River Laboratories, spending, trends qualifier

Charles River Laboratories, CRL, 2025 revenue outlook, CDMO business challenges, biopharma spending constraints, pharmaceutical industry trends

Samsung Biologics Embarks on New Phase of Growth with Bio Campus II and ADC Services

3 months ago talkbio0Tagged Antibody-Drug Conjugates, Bio Campus II, Biological Factors, Capacity, CDMO, Contract agreement, development aspects, digital transformation, expansion, Manufacturing Organization, Plants, Samsung, Services

Samsung Biologics, Bio Campus II, Plant 5, antibody-drug conjugate (ADC) services, capacity expansion, digital transformation, contract development and manufacturing organization (CDMO)